GSK and Novartis withdraw EU filings in cancer and influenza
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline and Novartis have each withdrawn a marketing authorisation application for Tyverb and Fluad respectively, the EMA has announced ahead of the outcome of this month's meeting of its advisory group, the Committee for Medicinal Products for Human Use (CHMP).